HRP20130093T1 - Formulacije 14-epi-analoga vitamina d - Google Patents
Formulacije 14-epi-analoga vitamina d Download PDFInfo
- Publication number
- HRP20130093T1 HRP20130093T1 HRP20130093AT HRP20130093T HRP20130093T1 HR P20130093 T1 HRP20130093 T1 HR P20130093T1 HR P20130093A T HRP20130093A T HR P20130093AT HR P20130093 T HRP20130093 T HR P20130093T HR P20130093 T1 HRP20130093 T1 HR P20130093T1
- Authority
- HR
- Croatia
- Prior art keywords
- oral formulation
- formulation according
- inecalcitol
- oral
- preceding patent
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims 15
- 239000000203 mixture Substances 0.000 title claims 15
- 229940046008 vitamin d Drugs 0.000 title claims 2
- BUDPDEVHCQIFNU-PUBYVPDWSA-N inecalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC#CC(C)(C)O)C)=C/C=C1/C[C@@H](O)C[C@H](O)C1=C BUDPDEVHCQIFNU-PUBYVPDWSA-N 0.000 claims 5
- 229950003028 inecalcitol Drugs 0.000 claims 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- -1 trochicus Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Oralna formulacija, naznačena time da je navedena formulacija suha formulacija koja sadrži:
inekalcitol,
karboksimetilcelulozu (CMC), i
jedan ili više izbornih farmaceutski prihvatljivih ekscipijenasa.
2. Oralna formulacija prema patentnom zahtjevu 1, naznačena time da sadrži između 0,1% i 50% (mase) CMC-a.
3. Oralna formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time da je koncentracija inekalcitola između 0,001 i 50% (mase).
4. Oralna formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time da je u jediničnoj dozi.
5. Oralna formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time da je u obliku tablete, pilule, praha, tvrde kapsule, pastile, trohiskusa, pastile koja se otapa u ustima.
6. Oralna formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time da nadalje sadrži vezivo, razrjeđivač, dezintegrant, lubrikant, glidant, antioksidans, sladilo ili aromu.
7. Oralna formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time da sadrži od 0,5 do 20 mg inekalcitola.
8. Oralna formulacija prema bilo kojem patentnom zahtjevu od 1 do 7, naznačena time da ima poboljšani profil apsorpcije inekalcitola u odnosu na formulaciju srednjolančanih triglicerida (MCT).
9. Oralna formulacija prema bilo kojem prethodnom patentnom zahtjevu, naznačena time da se koristi za sprječavanje i/ili liječenje rahitisa, osteoporoze, osteomalacije, psorijaze, autoimunih bolesti poput multiple skleroze ili dijabetesa tipa 1, hiperparatiroidizma, benigne hiperplazije prostate, bilo koje vrste raka ili bilo koje bolesti vezane uz vitamin D.
10. Oralna formulacija prema bilo kojem patentnom zahtjevu od 1 do 9, naznačena time da se koristi za poboljšanje apsorpcije inekalcitola u odnosu na formulaciju srednjolančanog triglicerida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305783A EP2407152A1 (en) | 2010-07-15 | 2010-07-15 | Formulations of 14-epi-analogues of vitamin D |
| US12/836,974 US20120015913A1 (en) | 2010-07-15 | 2010-07-15 | Formulations of 14-EPI-Analogues of Vitamin D |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130093T1 true HRP20130093T1 (hr) | 2013-02-28 |
Family
ID=44281019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130093AT HRP20130093T1 (hr) | 2010-07-15 | 2013-02-04 | Formulacije 14-epi-analoga vitamina d |
| HRP20130237AT HRP20130237T1 (hr) | 2010-07-15 | 2013-03-19 | Formulacije inekalcitola |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130237AT HRP20130237T1 (hr) | 2010-07-15 | 2013-03-19 | Formulacije inekalcitola |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2407155B1 (hr) |
| JP (2) | JP5836373B2 (hr) |
| KR (2) | KR101821440B1 (hr) |
| CN (2) | CN103096876A (hr) |
| AU (2) | AU2011278352B2 (hr) |
| BR (2) | BR112013000930A2 (hr) |
| CA (2) | CA2805198C (hr) |
| DK (2) | DK2407154T3 (hr) |
| ES (2) | ES2398640T3 (hr) |
| HR (2) | HRP20130093T1 (hr) |
| IL (2) | IL224192A (hr) |
| MX (1) | MX2013000539A (hr) |
| NZ (2) | NZ606679A (hr) |
| PL (2) | PL2407155T3 (hr) |
| PT (2) | PT2407155E (hr) |
| SG (2) | SG187071A1 (hr) |
| SI (2) | SI2407154T1 (hr) |
| WO (3) | WO2012007517A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120015913A1 (en) | 2010-07-15 | 2012-01-19 | Delansorne Remi | Formulations of 14-EPI-Analogues of Vitamin D |
| NZ606679A (en) * | 2010-07-15 | 2014-07-25 | Hybrigenics Sa | Formulations of 14-epi-analogues of vitamin d and cmc |
| WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
| WO2017211274A1 (en) * | 2016-06-08 | 2017-12-14 | Dong Yuhong | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001960A1 (en) | 1993-07-09 | 1995-01-19 | Laboratoire Theramex S.A. | Novel structural analogues of vitamin d |
| JPH10111593A (ja) * | 1996-10-04 | 1998-04-28 | Asahi Optical Co Ltd | 複写機の変倍光学装置 |
| US5936105A (en) | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| GB0305332D0 (en) | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
| US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| AU2004203436A1 (en) | 2003-09-24 | 2005-04-14 | Bioxell Spa | Compound and use in treatment |
| GB0423091D0 (en) * | 2004-10-19 | 2004-11-17 | Leuven K U Res & Dev | Bioactive vitamin d analogues |
| US20070093458A1 (en) * | 2005-07-18 | 2007-04-26 | Anchel Schwartz | Preparation of paricalcitol and crystalline forms thereof |
| US20080145411A1 (en) * | 2006-10-06 | 2008-06-19 | Kaneka Corporation | Composition of high absorbability for oral administration comprising oxidized coenzyme q10 |
| JP2010111593A (ja) * | 2008-11-04 | 2010-05-20 | Teijin Pharma Ltd | １４−エピ−１９−ノルプレビタミンｄ３誘導体 |
| PL2263677T3 (pl) * | 2009-05-20 | 2011-09-30 | Hybrigenics Sa | Nowe zastosowania terapeutyczne inekalcitolu |
| NZ606679A (en) * | 2010-07-15 | 2014-07-25 | Hybrigenics Sa | Formulations of 14-epi-analogues of vitamin d and cmc |
-
2011
- 2011-07-13 NZ NZ606679A patent/NZ606679A/en not_active IP Right Cessation
- 2011-07-13 PT PT111738605T patent/PT2407155E/pt unknown
- 2011-07-13 JP JP2013519097A patent/JP5836373B2/ja not_active Expired - Fee Related
- 2011-07-13 NZ NZ606678A patent/NZ606678A/en not_active IP Right Cessation
- 2011-07-13 DK DK11173836.5T patent/DK2407154T3/da active
- 2011-07-13 MX MX2013000539A patent/MX2013000539A/es active IP Right Grant
- 2011-07-13 SI SI201130012T patent/SI2407154T1/sl unknown
- 2011-07-13 DK DK11173860.5T patent/DK2407155T3/da active
- 2011-07-13 CA CA2805198A patent/CA2805198C/en not_active Expired - Fee Related
- 2011-07-13 SG SG2013002902A patent/SG187071A1/en unknown
- 2011-07-13 WO PCT/EP2011/061984 patent/WO2012007517A1/en active Application Filing
- 2011-07-13 KR KR1020137003059A patent/KR101821440B1/ko active IP Right Grant
- 2011-07-13 WO PCT/EP2011/061973 patent/WO2012007512A1/en active Application Filing
- 2011-07-13 EP EP11173860A patent/EP2407155B1/en not_active Not-in-force
- 2011-07-13 AU AU2011278352A patent/AU2011278352B2/en not_active Ceased
- 2011-07-13 BR BR112013000930A patent/BR112013000930A2/pt not_active Application Discontinuation
- 2011-07-13 BR BR112013000941A patent/BR112013000941A2/pt not_active Application Discontinuation
- 2011-07-13 ES ES11173836T patent/ES2398640T3/es active Active
- 2011-07-13 PT PT111738365T patent/PT2407154E/pt unknown
- 2011-07-13 PL PL11173860T patent/PL2407155T3/pl unknown
- 2011-07-13 AU AU2011278346A patent/AU2011278346B2/en not_active Ceased
- 2011-07-13 JP JP2013519093A patent/JP5836372B2/ja not_active Expired - Fee Related
- 2011-07-13 CN CN2011800432762A patent/CN103096876A/zh active Pending
- 2011-07-13 SI SI201130021T patent/SI2407155T1/sl unknown
- 2011-07-13 CA CA2805203A patent/CA2805203A1/en not_active Abandoned
- 2011-07-13 SG SG2013002910A patent/SG187072A1/en unknown
- 2011-07-13 EP EP11173836A patent/EP2407154B1/en not_active Not-in-force
- 2011-07-13 KR KR1020137003060A patent/KR101821441B1/ko active IP Right Grant
- 2011-07-13 PL PL11173836T patent/PL2407154T3/pl unknown
- 2011-07-13 ES ES11173860T patent/ES2401715T3/es active Active
- 2011-07-13 CN CN201180043277.7A patent/CN103096877B/zh not_active Expired - Fee Related
- 2011-07-15 WO PCT/EP2011/062127 patent/WO2012007570A2/en active Application Filing
-
2013
- 2013-01-13 IL IL224192A patent/IL224192A/en active IP Right Grant
- 2013-01-13 IL IL224191A patent/IL224191A/en active IP Right Grant
- 2013-02-04 HR HRP20130093AT patent/HRP20130093T1/hr unknown
- 2013-03-19 HR HRP20130237AT patent/HRP20130237T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5583012B2 (ja) | 口腔内速崩壊錠及びその製造方法 | |
| KR20120055559A (ko) | 퀴놀린 유도체 함유 의약 조성물 | |
| US20220218602A1 (en) | Oral pharmaceutical composition | |
| FI2508188T3 (fi) | Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita | |
| PH12015501523A1 (en) | Formulations of 4-amino-2-(2, 6-dioxopiperidine-3-yl) isiondoline-1, 3-dione | |
| EA201001852A1 (ru) | Твердые фармацевтические составы, содержащие bibw 2992 | |
| AR041370A1 (es) | Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion | |
| JP2011098964A5 (hr) | ||
| ES2435943T3 (es) | Formulaciones de vildagliptina | |
| AR069312A1 (es) | Composicion farmaceutica que comprende beta oxihidroxido de hierro en alta carga en forma adecuada para administarcion oral y que contiene al menos un hidrato de carbono y/o acido humico y su uso en el tratamiento de pacientes con hiperfosfatemia y con insuficiencia renal cronica , y procedimento pa | |
| HRP20130093T1 (hr) | Formulacije 14-epi-analoga vitamina d | |
| ES2923214T3 (es) | Composición farmacéutica que comprende mesilato de lenvatinib | |
| JP2013144717A (ja) | ピタバスタチン又はその塩の苦味抑制方法 | |
| JP2022088683A (ja) | 医薬組成物 | |
| KR101283147B1 (ko) | 로수바스타틴 칼슘의 약학적 조성물 | |
| JP2012527424A5 (hr) | ||
| ES2793724T3 (es) | Formulación pediátrica | |
| RU2013109765A (ru) | Стабильные составы шипучего бисфосфоната со свойствами быстрой солюбилизации | |
| PE20171321A1 (es) | Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion | |
| Huynh et al. | Floating tablets incorporating curcumin solid dispersion as a potential pharmaceutical dosage form for stomach cancer treatment | |
| ATE457721T1 (de) | An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen | |
| Patil et al. | Formulation and evaluation of oral disintegrating tablet of Lornoxicam | |
| JP2009073778A (ja) | グルクロノラクトン含有固形製剤 | |
| ES2922903T3 (es) | Composición farmacéutica que comprende sales de lenvatinib | |
| TWI740994B (zh) | 經光穩定性提升之固體製劑 |